Wickham Micro

Building a leading medical device testing platform enabling innovators and OEMs to develop and deliver critical devices to patients safely and rapidly all to regulatory standards.


What we're doing

The first business in WMP is Wickham Micro, a leading microbiology laboratory to the UK Medical Devices and Pharma sectors.  Wickham Micro helps innovators and manufacturers ensure that their products are suitably sterile for their intended use with patients.

Wickham Micro was sourced privately, with initial direct contact in 2018 leading to subsequent deal structure and outcome in 2021 as the initial platform for WMP.  We acquired Wickham Micro through an asset purchase from parent company Wickham Laboratories Ltd, carving out their in vivo toxicology business into a separate entity.

We were attracted to the investment by the stability of the business, strong cash flow conversion, and the opportunity for re-investing cashflows and accretive M&A in the fragmented UK and US markets.

Limerston is actively deligencing laboratories providing analytical chemistry and physical performance testing along with additional microbiology services across the UK, EU, and the USA to build a global market leader in Medical Device safety testing.

Overall, this is the first of a targeted 8-10 labs that will form the WMP group. Sourcing continues for additional investments across analytical chemistry, physical safety performance testing, and microbiology testing in the UK, EU, and USA. 

Within Wickham, the Limerston team have been supporting a number of programs, including:


  • Providing interim CEO cover whilst recruiting Group CEO

  • Working with the team to carve out the in vivo toxicology unit into a separate entity, along with the regulatory and legal practicalities of an asset purchase in a heavily regulated environment

  • Implementing a LEAN six sigma program on both laboratory and non-laboratory processes

  • Supporting with IT leadership to enhance existing systems and upgrade the LIMS system

  • Investing in key technologies across sterility, microbial identifications, and rapid microbiological methods to enable our clients to launch and release products safely within the regulations to the patients that need them

  • Investing in more sustainable (environmentally and economically) air handling across the site


Key takeaways

Life Sciences / MedTech

Year Invested


Deal Type

Private sale, asset purchase and carve out


60 Years 

Established 1962

Over 200

clients supported every year

10% p.a.

Established market growth